Skip to main content

Bioxodes closes €12 million in Series A funding round

Bioxodes closes €12 million in  Series A funding round Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023 Gosselies, Belgium, November 21, 2023 – Bioxodes SA, a biopharmaceutical company specializing…

Read More

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts…

Read More

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy DeuterOncology obtains SPW grant funding Liège, Belgium, April 07, 2023 – DeuterOncology, a Liège-Based (BE) biotech company, is pleased to announce it has successfully been awarded the Win4Company grant by the Wallonie recherche SPW. The clinical-stage drug...
Read More

ImmuneWatch, Quantoom Biosciences (Univercells) and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines

March 30, 2023 Quantoom Biosciences (“Quantoom”), ImmuneWatch and UAntwerp (Lab of Experimental Hematology) are delighted to announce a public-private partnership in a project under the “Pandemic Preparedness” call, launched by the University of Antwerp in 2022. “The goal of this project is to assess if a detailed analysis of the...
Read More

Quantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry (Région Île-de-France)

Brussels (Belgium) – March 2, 2023 Quantoom Biosciences S.A. (“Quantoom”), a Belgian biotech with the mission to reinvent mRNA production announces today the opening of a brand-new facility in Évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but these…

Read More

ABSCINT and the VUB announce a Notice of Allowance for their U.S. Patent covering diagnostic applications of its single-domain antibody labelled with radioisotopes for PET/CT imaging of HER2 cancer lesions

  Brussels, Liège, February 20, 2023. Vrije Universiteit Brussel (VUB) and its spin-off ABSCINT announce today that the United States Patent and Trademark Office (“USPTO”) has provided a Notice of Allowance for patent application No. 16/827,032, entitled “Radio-labelled antibody fragments for use in the prognosis and diagnosis of cancer as well as for the…

Read More